Skip to main content
SINPHAR logo

SINPHAR — Investor Relations & Filings

Ticker · 1734 ISIN · TW0001734002 TW Manufacturing
Open in API
Filings indexed 1,611 across all filing types
Latest filing 2022-11-14 Regulatory Filings
Country TW Taiwan
Listing TW 1734

About SINPHAR

www.sinphar.com

Sinphar Pharmaceutical Co., Ltd. is a vertically integrated pharmaceutical group specializing in the research, development, manufacturing, and distribution of therapeutic medicines, nutraceuticals, and medical cosmetics. Established in 1977, the company produces a diverse range of products, including Western and Chinese pharmaceuticals, specialized oncology drugs, and health supplements. Sinphar operates advanced R&D facilities and an ISO 17025-certified laboratory, leveraging high-precision technology for product innovation and quality assurance. Its business model encompasses proprietary brand management alongside professional OEM and ODM services for international markets. Key areas of expertise include the development of cancer treatments, functional health foods, and medical-grade skincare. Through its global marketing network and dedicated retail counters, Sinphar provides comprehensive healthcare solutions focused on life, health, and technology.

Recent filings

Filing Released Lang Actions
111年第3季海外子公司投資
Regulatory Filings Classification · 95% confidence The document is a financial disclosure from a publicly listed company, 杏輝, reporting investment details in overseas subsidiaries for the third quarter of the 111th year (likely referring to the Taiwanese calendar year). It includes investment amounts, shareholding percentages, and recognized investment gains or losses. The document length is only 1065 characters, which is quite short and contains tabular financial data but no comprehensive financial statements or detailed analysis. It appears to be a regulatory disclosure of investment holdings rather than a full financial report or earnings release. Given the short length and nature of the content, it fits best as a Regulatory Filing (RNS), which is a fallback category for miscellaneous regulatory disclosures that do not fit other specific categories.
2022-11-14 Chinese
111年第3季大陸投資
Regulatory Filings Classification · 95% confidence The document is a detailed tabular disclosure of investment amounts, investment methods, and investment income related to the company's investments in mainland China. It includes financial figures for the current period and cumulative investments, as well as notes explaining the investment methods and accounting treatments. The document is relatively short (1502 characters) and appears to be a regulatory disclosure of investment information rather than a full financial report or earnings release. There is no indication that this is an annual or interim report, audit report, or earnings release. It is not a meeting-related document or a capital/financing update. The content fits best with a Regulatory Filing (RNS) as it is a compliance disclosure of investment information required by regulatory authorities, without substantive financial statements or management discussion.
2022-11-14 Chinese
111年第3季財務報告書 — 202204_1734_AIC.pdf
Audit Report / Information Classification · 95% confidence The document is titled 'Parent Company Only Financial Statements for the Years Ended December 31, 2022 and 2021 and Independent Auditors’ Report' for Sinphar Pharmaceutical Co., Ltd. It contains an Independent Auditors' Report with an opinion on the financial statements, detailed audit procedures, key audit matters, and extensive financial data including balance sheets, notes, and disclosures for the years ended December 31, 2022 and 2021. The content is comprehensive, includes actual financial statements and notes, and is not merely an announcement or certification. This matches the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles, distinct from a full Annual Report (10-K). Therefore, the document is best classified as an Audit Report / Information (AR).
2022-11-14 Chinese
111年第3季財務報告書 — 202204_1734_AIA.pdf
Annual Report Classification · 100% confidence The document is titled 'Consolidated Financial Statements for the Years Ended December 31, 2022 and 2021 and Independent Auditors’ Report' for Sinphar Pharmaceutical Co., Ltd. It contains detailed financial statements including balance sheets, income statements, cash flows, notes on accounting policies, and an independent auditor's opinion. The content includes extensive audit procedures, key audit matters, management responsibilities, and auditor responsibilities, all typical of a full annual financial report. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement or certification. The presence of consolidated financial statements for a full fiscal year and the auditor's report confirms this is an Annual Report (10-K equivalent).
2022-11-14 Chinese
111年第3季財務報告書 — 202204_1734_AI3.pdf
Regulatory Filings
2022-11-14 Chinese
111年第3季財務報告書 — 202204_1734_AI1.pdf
Regulatory Filings
2022-11-14 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.